ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen and Simcere Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenSimcere Pharmaceutical Group
studies on the registry1,08882
open to participants now5015
phase 3 studies under way505
reach primary completion within a year356
programswith a study of their own in two years2416

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenSimcere Pharmaceutical Group
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Simcere Pharmaceutical Group: 9 of its 16 programs at phase 1

  1. dose expansion of SIM0609 in GC/GEJC cohortphase 1
  2. SIM0388phase 1
  3. SIM0518phase 1
  4. SIM0532phase 1
  5. SIM0609phase 1

and 4 more — sign in to see them all

56%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Simcere Pharmaceutical Group: 1 of its 16 programs at phase 2

  1. SIM0278phase 2
6%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Simcere Pharmaceutical Group: 5 of its 16 programs at phase 3

  1. SIM0270phase 3
  2. suvemcitugphase 3
  3. SIM0811phase 3
  4. tipiracilphase 3
  5. Trifluridinephase 3
31%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Simcere Pharmaceutical Group: 1 of its 16 programs at approved, new studies

  1. trilaciclibapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Simcere Pharmaceutical Group2 readouts · 1 phase 3·······

Simcere Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion

  1. SIM0388phase 1 · Jun 0 · NCT07007988

Simcere Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trilaciclibapproved, new study · Jul 15 · NCT07881705
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

Simcere Pharmaceutical Group

New programs 1

  • SIM0518phase 1 · first study · Oct 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • SIM0811phase 3 · Oct 23 · Ischemic Stroke

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionAmgenSimcere Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungboth · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. sotorasibphase 3
  2. etakafusp alfaphase 1
  3. Pan-KRAS Inhibitor AMG 410phase 1
  4. tambotatug pelitecanphase 1
  5. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Simcere Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. SIM0518phase 1
  2. SIM0610phase 1
  3. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Simcere Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. suvemcitugphase 3
  2. tipiracilphase 3
  3. Trifluridinephase 3
  4. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Simcere Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Neoplasmsboth · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Simcere Pharmaceutical Group in Neoplasms: 1 program

  1. SIM0689phase 1

Their studies: Simcere Pharmaceutical Group’s studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAmgenSimcere Pharmaceutical Group
VEGFAafliberceptrulesuvemcitugrule, SIM0689rule
A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Simcere Pharmaceutical Group 7 of 16 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.